【作者单位】Department of Geriatrics, West China Fourth Hospital, Sichuan University, Chengdu, China;Xindu Hospital of Traditional Chinese Medicine, Chengdu, China;Department of Geriatrics, West China Fourth Hospital, Sichuan University, Chengdu, China;Tibet University Medical College, Lasha, China;Department of Geriatrics, West China Fourth Hospital, Sichuan University, Chengdu, China;Peiwei Hong, Department of Geriatrics, West China Fourth Hospital, Sichuan University, Chengdu, China.
【摘要】 Background CGRP monoclonal antibody is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy a...
